A4Cell has developed SPAchip®, silicon microchips designed to study live single cells in vitro without compromising cell viability. The chips can monitor multiple intracellular parameters or molecules simultaneously in real time and over extended periods. The company highlights advantages versus soluble fluorescent probes, including reduced toxicity, longer monitoring windows, and multiplexing capability. Hospitals and pharmaceutical and biotechnology companies are cited as key users of single-cell analysis for drug mechanism studies and target discovery. Management says the new funding will allow the company to intensify R&D and advance product development aimed at unlocking insights from individual living cells. CEO Elena Rivas described the investment as a crucial moment that underscores A4Cell’s commitment to expanding single-cell analysis capabilities, particularly for complex diseases like cancer.

Total raised

$3M

Funding rounds

1

Latest round

Equity

Latest activity

Nov 2023